The future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches
暂无分享,去创建一个
[1] J. Taylor-Cousar,et al. CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis , 2023, The Lancet.
[2] S. Birket,et al. Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy. , 2023, The Lancet. Respiratory medicine.
[3] J. Pilewski,et al. Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective. , 2023, The Lancet. Respiratory medicine.
[4] M. Ziehm,et al. Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis , 2023, European Respiratory Journal.
[5] B. Ramsey,et al. Cystic Fibrosis: A Review. , 2023, JAMA.
[6] Daiki Matsuda,et al. Engineered tRNAs suppress nonsense mutations in cells and in vivo , 2023, Nature.
[7] A. Healy,et al. A novel thiol-saccharide mucolytic for the treatment of muco-obstructive lung diseases , 2023, European Respiratory Journal.
[8] T. Liou,et al. Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double-blind, placebo-controlled phase 1/2 clinical study. , 2023, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[9] N. Jacquier,et al. Recent advances in therapeutic targets identification and development of treatment strategies towards Pseudomonas aeruginosa infections , 2023, BMC Microbiology.
[10] L. Hoffman,et al. Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist , 2023, The Journal of clinical investigation.
[11] M. Rosenfeld,et al. Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One F508del Allele , 2023, American journal of respiratory and critical care medicine.
[12] P. Burgel,et al. The French compassionate programme of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant , 2023, European Respiratory Journal.
[13] P. Sosnay,et al. Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials. , 2023, The Lancet. Respiratory medicine.
[14] P. Burgel,et al. Role of inhaled antibiotics in the era of highly effective CFTR modulators , 2023, European Respiratory Review.
[15] J. Lueck,et al. Gene, RNA, and ASO-based therapeutic approaches in Cystic Fibrosis. , 2023, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[16] G. Criner,et al. Cystic fibrosis transmembrane conductance regulator in COPD: a role in respiratory epithelium and beyond , 2022, European Respiratory Journal.
[17] A. Ramalho,et al. Patient-derived cell models for personalized medicine approaches in cystic fibrosis. , 2022, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[18] J. Fothergill,et al. Challenges and opportunities in the development of novel antimicrobial therapeutics for cystic fibrosis. , 2022, Journal of medical microbiology.
[19] G. Cimino,et al. Elexacaftor/tezacaftor/ivacaftor corrects monocyte microbicidal deficiency in cystic fibrosis , 2022, European Respiratory Journal.
[20] T. Murray,et al. Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis. , 2022, Clinics in chest medicine.
[21] K. McCoy,et al. Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor , 2022, European Respiratory Journal.
[22] Jue Chen,et al. Molecular Structures Reveal Synergistic Rescue of Δ508 CFTR by Trikafta Modulators , 2022, Science.
[23] M. Amaral,et al. Development of novel therapeutics for all individuals with CF (the future goes on). , 2022, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[24] J. Davies,et al. Progress in Respiratory Gene Therapy , 2022, Human gene therapy.
[25] D. Prais,et al. Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study , 2022, American journal of respiratory and critical care medicine.
[26] P. Harrison. CFTR RNA- and DNA-based therapies. , 2022, Current opinion in pharmacology.
[27] J. Rommens,et al. Genetic evidence supports the development of SLC26A9 targeting therapies for the treatment of lung disease , 2022, npj Genomic Medicine.
[28] B. Fleischmann,et al. A PI3Kγ mimetic peptide triggers CFTR gating, bronchodilation, and reduced inflammation in obstructive airway diseases , 2022, Science Translational Medicine.
[29] L. Galietta. TMEM16A (ANO1) as a therapeutic target in cystic fibrosis. , 2022, Current opinion in pharmacology.
[30] E. Hoffman,et al. Elastic mucus strands impair mucociliary clearance in cystic fibrosis pigs , 2022, Proceedings of the National Academy of Sciences of the United States of America.
[31] F. Zara,et al. SLC26A9 as a Potential Modifier and Therapeutic Target in Cystic Fibrosis Lung Disease , 2022, Biomolecules.
[32] D. Hill,et al. Physiology and Pathophysiology of Human Airway Mucus. , 2022, Physiological reviews.
[33] O. Sommerburg,et al. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two F508del Alleles. , 2021, American journal of respiratory and critical care medicine.
[34] R. Fischer,et al. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial. , 2021, The Lancet. Respiratory medicine.
[35] B. Kerem,et al. Antisense oligonucleotide splicing modulation as a novel Cystic Fibrosis therapeutic approach for the W1282X nonsense mutation. , 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[36] M. Gentzsch,et al. Impact of Airway Inflammation on the Efficacy of CFTR Modulators , 2021, Cells.
[37] J. Lueck,et al. Efficient suppression of endogenous CFTR nonsense mutations using anticodon-engineered transfer RNAs , 2021, bioRxiv.
[38] G. Koppelman,et al. Functional Restoration of CFTR Nonsense Mutations in Intestinal Organoids. , 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[39] D. Waltz,et al. Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes. , 2021, The New England journal of medicine.
[40] H. Clevers,et al. Evaluating CRISPR-based prime editing for cancer modeling and CFTR repair in organoids , 2021, Life Science Alliance.
[41] R. Green,et al. A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion , 2021, Nature Communications.
[42] J. Davies,et al. Cystic fibrosis , 2021, The Lancet.
[43] R. Gibson,et al. A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele , 2021, American journal of respiratory and critical care medicine.
[44] I. Baumann,et al. Chronic Rhinosinusitis with Nasal Polyps is Associated with Impaired TMEM16A-mediated Epithelial Chloride Secretion. , 2021, The Journal of allergy and clinical immunology.
[45] B. Kerem,et al. Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849 + 10 kb C-to-T splicing mutation , 2021, bioRxiv.
[46] S. McColley,et al. Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype , 2021, Pediatric pulmonology.
[47] T. Haverty,et al. A Randomized, Double‐Blind, Placebo‐Controlled, Multiple Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of ELX‐02 in Healthy Subjects , 2021, Clinical pharmacology in drug development.
[48] C. López-Otín,et al. Hallmarks of Health , 2020, Cell.
[49] L. Ostrowski,et al. Secretory Cells Dominate Airway CFTR Expression and Function in Human Airway Superficial Epithelia. , 2020, American journal of respiratory and critical care medicine.
[50] Adan Chari Jirmo,et al. Rescue from Pseudomonas aeruginosa airway infection via stem cell transplantation. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.
[51] Meilan K. Han,et al. Mucus Plugs and Emphysema in the Pathophysiology of Airflow Obstruction and Hypoxemia in Smokers. , 2020, American journal of respiratory and critical care medicine.
[52] E. Kerem. ELX-02: an investigational read-through agent for the treatment of nonsense mutation-related genetic disease , 2020, Expert opinion on investigational drugs.
[53] M. Griese,et al. Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial , 2020, American journal of respiratory and critical care medicine.
[54] Fabian J Theis,et al. LifeTime and improving European healthcare through cell-based interceptive medicine , 2020, Nature.
[55] A. O'donnell,et al. Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. , 2020, The New England journal of medicine.
[56] C. Verfaillie,et al. Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis , 2020, European Respiratory Journal.
[57] M. Mall. ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies , 2020, European Respiratory Journal.
[58] I. Heimbeck,et al. Single dose escalation studies with inhaled POL6014, a potent novel selective reversible inhibitor of human neutrophil elastase, in healthy volunteers and subjects with cystic fibrosis. , 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[59] H. Clevers,et al. CRISPR-Based Adenine Editors Correct Nonsense Mutations in a Cystic Fibrosis Organoid Biobank. , 2020, Cell stem cell.
[60] D. McAuley,et al. Targeting Proteases in Cystic Fibrosis Lung Disease: Paradigms, Progress, and Potential. , 2020, American journal of respiratory and critical care medicine.
[61] H. Danahay,et al. TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic Fibrosis , 2020, American journal of respiratory and critical care medicine.
[62] S. Rowe,et al. Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications. , 2019, American journal of respiratory and critical care medicine.
[63] V. Waters,et al. Microbiology of Cystic Fibrosis Airway Disease , 2019, Seminars in Respiratory and Critical Care Medicine.
[64] Gareth W. Hughes,et al. The MUC5B mucin polymer is dominated by repeating structural motifs and its topology is regulated by calcium and pH , 2019, Scientific Reports.
[65] C. Teneback,et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial , 2019, The Lancet.
[66] L. Lands,et al. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. , 2019, The New England journal of medicine.
[67] R. Boucher. Muco‐Obstructive Lung Diseases , 2019, The New England journal of medicine.
[68] D. Waltz,et al. Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles , 2019, ERJ Open Research.
[69] P. Negulescu,et al. In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis , 2019, Science Translational Medicine.
[70] Boya Wang,et al. An Improved Inhaled Mucolytic to Treat Airway Muco‐obstructive Diseases , 2019, American journal of respiratory and critical care medicine.
[71] J. Wallenburg,et al. CFTR modulator theratyping: Current status, gaps and future directions. , 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[72] A. Chang,et al. Bronchiectasis , 2018, Nature Reviews Disease Primers.
[73] A. Orth,et al. Structure-guided combination therapy to potently improve the function of mutant CFTRs , 2018, Nature Medicine.
[74] A. Balázs,et al. Role of the SLC26A9 Chloride Channel as Disease Modifier and Potential Therapeutic Target in Cystic Fibrosis , 2018, Front. Pharmacol..
[75] J. Lipuma,et al. Cystic fibrosis respiratory microbiota: unraveling complexity to inform clinical practice , 2018, Expert review of respiratory medicine.
[76] J. Lueck,et al. Engineered transfer RNAs for suppression of premature termination codons , 2018, Nature Communications.
[77] M. Gentzsch,et al. Ion Channel Modulators in Cystic Fibrosis , 2018, Chest.
[78] B. Tümmler,et al. Effects of Lumacaftor‐Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis , 2018, American journal of respiratory and critical care medicine.
[79] E. Hoffman,et al. Infection Is Not Required for Mucoinflammatory Lung Disease in CFTR‐Knockout Ferrets , 2018, American journal of respiratory and critical care medicine.
[80] M. Wolfgang,et al. Initial acquisition and succession of the cystic fibrosis lung microbiome is associated with disease progression in infants and preschool children , 2018, PLoS pathogens.
[81] I. Klimant,et al. Airway surface liquid pH is not acidic in children with cystic fibrosis , 2017, Nature Communications.
[82] A. Kicic,et al. The potential of phage therapy in cystic fibrosis: Essential human-bacterial-phage interactions and delivery considerations for use in Pseudomonas aeruginosa-infected airways. , 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[83] N. Rousselet,et al. MicroRNA-9 downregulates the ANO1 chloride channel and contributes to cystic fibrosis lung pathology , 2017, Nature Communications.
[84] R. Finkel,et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study , 2016, The Lancet.
[85] A. Doherty,et al. Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis , 2016, Thorax.
[86] Garry R. Cutting,et al. From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations , 2016, Molecular biology of the cell.
[87] David K. Meyerholz,et al. Airway acidification initiates host defense abnormalities in cystic fibrosis mice , 2016, Science.
[88] B. Byrne,et al. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy , 2015, Annals of neurology.
[89] T. Welte,et al. Hypoxic epithelial necrosis triggers neutrophilic inflammation via IL-1 receptor signaling in cystic fibrosis lung disease. , 2015, American journal of respiratory and critical care medicine.
[90] S. Hazen,et al. Oxidation increases mucin polymer cross-links to stiffen airway mucus gels , 2015, Science Translational Medicine.
[91] D. Meyerholz,et al. Origins of cystic fibrosis lung disease. , 2015, The New England journal of medicine.
[92] B. Marsland,et al. Host–microorganism interactions in lung diseases , 2014, Nature Reviews Immunology.
[93] S. Donaldson,et al. Cystic fibrosis airway secretions exhibit mucin hyperconcentration and increased osmotic pressure. , 2014, The Journal of clinical investigation.
[94] N. Pedemonte,et al. Structure and function of TMEM16 proteins (anoctamins). , 2014, Physiological reviews.
[95] Peter D Sly,et al. Risk factors for bronchiectasis in children with cystic fibrosis. , 2013, The New England journal of medicine.
[96] R. Moss. Pitfalls of drug development: lessons learned from trials of denufosol in cystic fibrosis. , 2013, The Journal of pediatrics.
[97] J. Sallenave,et al. Neutrophil elastase degrades cystic fibrosis transmembrane conductance regulator via calpains and disables channel function in vitro and in vivo. , 2013, American journal of respiratory and critical care medicine.
[98] Todd A. Durham,et al. Long term effects of denufosol tetrasodium in patients with cystic fibrosis. , 2012, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[99] D. Hill,et al. A Periciliary Brush Promotes the Lung Health by Separating the Mucus Layer from Airway Epithelia , 2012, Science.
[100] Hans Clevers,et al. A functional CFTR assay using primary cystic fibrosis intestinal organoids , 2013, Nature Medicine.
[101] M. Welsh,et al. Reduced Airway Surface pH Impairs Bacterial Killing in the Porcine Cystic Fibrosis Lung , 2012, Nature.
[102] S. Randell,et al. Mucus clearance, MyD88-dependent and MyD88-independent immunity modulate lung susceptibility to spontaneous bacterial infection and inflammation , 2012, Mucosal Immunology.
[103] K. Du,et al. Correction of Both NBD1 Energetics and Domain Interface Is Required to Restore ΔF508 CFTR Folding and Function , 2012, Cell.
[104] Philip J. Thomas,et al. Requirements for Efficient Correction of ΔF508 CFTR Revealed by Analyses of Evolved Sequences , 2012, Cell.
[105] J. Fahy,et al. Airway mucus function and dysfunction. , 2010, The New England journal of medicine.
[106] P. Quinton. Role of epithelial HCO3⁻ transport in mucin secretion: lessons from cystic fibrosis. , 2010, American journal of physiology. Cell physiology.
[107] Raymond Farley,et al. Toward gene therapy for cystic fibrosis using a lentivirus pseudotyped with Sendai virus envelopes. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[108] Roberto Ravazzolo,et al. TMEM16A, A Membrane Protein Associated with Calcium-Dependent Chloride Channel Activity , 2008, Science.
[109] P. Quinton. Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis , 2008, The Lancet.
[110] J. Riordan,et al. CFTR function and prospects for therapy. , 2008, Annual review of biochemistry.
[111] R. Kronmal,et al. Association between pulmonary function and sputum biomarkers in cystic fibrosis. , 2007, American journal of respiratory and critical care medicine.
[112] R. Boucher. Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. , 2007, Annual review of medicine.
[113] V. Bindokas,et al. CFTR regulates phagosome acidification in macrophages and alters bactericidal activity , 2006, Nature Cell Biology.
[114] Richard C Boucher,et al. Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice , 2004, Nature Medicine.
[115] B. Kerem,et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. , 2003, The New England journal of medicine.
[116] S. Emerson,et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study , 2003, The Lancet.
[117] Min Goo Lee,et al. Aberrant CFTR-dependent HCO-3 transport in mutations associated with cystic fibrosis , 2001, Nature.
[118] S. Randell,et al. Evidence for Periciliary Liquid Layer Depletion, Not Abnormal Ion Composition, in the Pathogenesis of Cystic Fibrosis Airways Disease , 1998, Cell.
[119] M. Welsh,et al. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis , 1993, Cell.
[120] L. Cantley,et al. Na+ transport in cystic fibrosis respiratory epithelia. Abnormal basal rate and response to adenylate cyclase activation. , 1986, The Journal of clinical investigation.
[121] C. Goss,et al. The future of cystic fibrosis care: a global perspective. , 2020, The Lancet. Respiratory medicine.
[122] M. Corey,et al. Correlating CFTR Function with Clinical Features to Inform Precision Treatment of Cystic Fibrosis , 2019 .
[123] M. Welsh,et al. Structure and function of the CFTR chloride channel. , 1999, Physiological reviews.